Table 4.
Issues discussed with patients before referral to Phase I trials? (single choice).
| (1) Aims of Phase I (dose finding and toxicity) | 25% |
| (2) Possibility of any clinical benefit | 23% |
| (3) Chance of helping future cancer patients | 17% |
| (4) Specific chance of response to Phase I | 15% |
| (5) Risk of side effects | 14% |
| (6) Specific drugs that could potentially help | 3% |
| (7) Others ( Travel required ) | 3% |